Anti-TNF-α therapy in the treatment of rheumatoid arthritis

Masao Sato, Masao Takemura, Ryuki Shinohe, Kuniaki Saito, Mitsuru Seishima

Research output: Contribution to journalArticle

Abstract

The etiology of rheumatoid arthritis (RA) is not known and its pathogenesis is complicated. However, tumor necrosis factor-α (TNF-α) has an important role in the pathogenesis of RA. There are two anti-TNF biological drugs, anti-TNF monoclonal antibodies (infliximab) and TNF receptors (etanercept), that we are able to use for RA patients in Japan. In this article, we introduced these anti-TNF biologies and their clinical efficacy from our experiences in patients with RA. Anti-TNF biologies improved the C reactive protein (CRP) levels and the disease activity score (DAS) 28. TNF-α and interleukin-6 (IL-6) levels were decreased in the course of infliximab therapy. In contrast, TNF-α levels were increased in etanercept therapy. Although anti-TNF biologies appear to have good efficacy for RA patients, careful attention must be paid to possible infections, such as tuberculosis, bronchitis, and Pneumocystis jiroveci. Another biologies for RA treatment will be approved in Japan in near future. We must provide the proper treatment using biologies in RA patients.

Original languageEnglish
Pages (from-to)176-180
Number of pages5
JournalBiotherapy
Volume21
Issue number3
Publication statusPublished - 01-05-2007
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Therapeutics
Japan
Pneumocystis carinii
Bronchitis
Tumor Necrosis Factor Receptors
C-Reactive Protein
Interleukin-6
Tuberculosis
Monoclonal Antibodies
Infection
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sato, M., Takemura, M., Shinohe, R., Saito, K., & Seishima, M. (2007). Anti-TNF-α therapy in the treatment of rheumatoid arthritis. Biotherapy, 21(3), 176-180.
Sato, Masao ; Takemura, Masao ; Shinohe, Ryuki ; Saito, Kuniaki ; Seishima, Mitsuru. / Anti-TNF-α therapy in the treatment of rheumatoid arthritis. In: Biotherapy. 2007 ; Vol. 21, No. 3. pp. 176-180.
@article{126260d6ecd84c96a2e33816ce486918,
title = "Anti-TNF-α therapy in the treatment of rheumatoid arthritis",
abstract = "The etiology of rheumatoid arthritis (RA) is not known and its pathogenesis is complicated. However, tumor necrosis factor-α (TNF-α) has an important role in the pathogenesis of RA. There are two anti-TNF biological drugs, anti-TNF monoclonal antibodies (infliximab) and TNF receptors (etanercept), that we are able to use for RA patients in Japan. In this article, we introduced these anti-TNF biologies and their clinical efficacy from our experiences in patients with RA. Anti-TNF biologies improved the C reactive protein (CRP) levels and the disease activity score (DAS) 28. TNF-α and interleukin-6 (IL-6) levels were decreased in the course of infliximab therapy. In contrast, TNF-α levels were increased in etanercept therapy. Although anti-TNF biologies appear to have good efficacy for RA patients, careful attention must be paid to possible infections, such as tuberculosis, bronchitis, and Pneumocystis jiroveci. Another biologies for RA treatment will be approved in Japan in near future. We must provide the proper treatment using biologies in RA patients.",
author = "Masao Sato and Masao Takemura and Ryuki Shinohe and Kuniaki Saito and Mitsuru Seishima",
year = "2007",
month = "5",
day = "1",
language = "English",
volume = "21",
pages = "176--180",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Gan To Kagaku Ryohosha",
number = "3",

}

Sato, M, Takemura, M, Shinohe, R, Saito, K & Seishima, M 2007, 'Anti-TNF-α therapy in the treatment of rheumatoid arthritis', Biotherapy, vol. 21, no. 3, pp. 176-180.

Anti-TNF-α therapy in the treatment of rheumatoid arthritis. / Sato, Masao; Takemura, Masao; Shinohe, Ryuki; Saito, Kuniaki; Seishima, Mitsuru.

In: Biotherapy, Vol. 21, No. 3, 01.05.2007, p. 176-180.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-TNF-α therapy in the treatment of rheumatoid arthritis

AU - Sato, Masao

AU - Takemura, Masao

AU - Shinohe, Ryuki

AU - Saito, Kuniaki

AU - Seishima, Mitsuru

PY - 2007/5/1

Y1 - 2007/5/1

N2 - The etiology of rheumatoid arthritis (RA) is not known and its pathogenesis is complicated. However, tumor necrosis factor-α (TNF-α) has an important role in the pathogenesis of RA. There are two anti-TNF biological drugs, anti-TNF monoclonal antibodies (infliximab) and TNF receptors (etanercept), that we are able to use for RA patients in Japan. In this article, we introduced these anti-TNF biologies and their clinical efficacy from our experiences in patients with RA. Anti-TNF biologies improved the C reactive protein (CRP) levels and the disease activity score (DAS) 28. TNF-α and interleukin-6 (IL-6) levels were decreased in the course of infliximab therapy. In contrast, TNF-α levels were increased in etanercept therapy. Although anti-TNF biologies appear to have good efficacy for RA patients, careful attention must be paid to possible infections, such as tuberculosis, bronchitis, and Pneumocystis jiroveci. Another biologies for RA treatment will be approved in Japan in near future. We must provide the proper treatment using biologies in RA patients.

AB - The etiology of rheumatoid arthritis (RA) is not known and its pathogenesis is complicated. However, tumor necrosis factor-α (TNF-α) has an important role in the pathogenesis of RA. There are two anti-TNF biological drugs, anti-TNF monoclonal antibodies (infliximab) and TNF receptors (etanercept), that we are able to use for RA patients in Japan. In this article, we introduced these anti-TNF biologies and their clinical efficacy from our experiences in patients with RA. Anti-TNF biologies improved the C reactive protein (CRP) levels and the disease activity score (DAS) 28. TNF-α and interleukin-6 (IL-6) levels were decreased in the course of infliximab therapy. In contrast, TNF-α levels were increased in etanercept therapy. Although anti-TNF biologies appear to have good efficacy for RA patients, careful attention must be paid to possible infections, such as tuberculosis, bronchitis, and Pneumocystis jiroveci. Another biologies for RA treatment will be approved in Japan in near future. We must provide the proper treatment using biologies in RA patients.

UR - http://www.scopus.com/inward/record.url?scp=34250872811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250872811&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34250872811

VL - 21

SP - 176

EP - 180

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -

Sato M, Takemura M, Shinohe R, Saito K, Seishima M. Anti-TNF-α therapy in the treatment of rheumatoid arthritis. Biotherapy. 2007 May 1;21(3):176-180.